<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949325</url>
  </required_header>
  <id_info>
    <org_study_id>J0963</org_study_id>
    <secondary_id>NA_00028490</secondary_id>
    <nct_id>NCT00949325</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma</brief_title>
  <official_title>Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Comprehensive Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify a safe dosing regimen for the combination of Torisel
      and liposomal doxorubicin in patients with recurrent sarcoma. A secondary purpose of the
      study is to determine how effective this combination is for the treatment of recurrent
      sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effectiveness of treatments for recurrent sarcomas is quite limited. One hypothesis to
      explain the refractory nature of recurrent sarcomas is the existence of
      chemotherapy-resistant sarcoma stem cells.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the pharmacokinetics of Torisel when administered with liposomal doxorubicin</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2-4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>2-4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>2-4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the activity of the mTOR signaling pathway before and after therapy with Torisel and liposomal doxorubicin</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the proportion of cells with stem cell properties in tumors before and after treatment with Torisel and liposomal doxorubicin</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>2-4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Temsirolimus plus Liposomal Doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm: Temsirolimus is administered IV in cohorts of sequentially escalating cohorts at doses between 15 and 50 mg/M2 (body surface area), once weekly. Liposomal doxorubicin is administered IV at a dose of 30 mg per M2 (body surface area) once every 28 days. Treatment may continue with both drugs for 2 years. Treatment with Temsirolimus may continue beyond 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)</intervention_name>
    <description>Patients will be treated with temsirolimus weekly by iv and with liposomal doxorubicin (standard dose) by iv once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until maximally tolerated dose (MTD) is reached. Once MTD (standard dose) is achieved, dosing will be with standard doses for each drug, but dosing will be modified based on toxicity.</description>
    <arm_group_label>Temsirolimus plus Liposomal Doxorubicin</arm_group_label>
    <other_name>Torisel</other_name>
    <other_name>Doxil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed sarcoma that is recurrent or refractory to conventional
             treatment

          -  Measurable disease by RECIST criteria

          -  ECOG performance status &lt; 2 (or Lansky/Karnofsky &gt; 60% for children)

          -  Life expectancy greater than 3 months

          -  Adequate organ function

          -  absolute neutrophil count at least 1,500

          -  platelets at least 100,000

          -  bilirubin less than 1.5 x upper limit of normal

          -  AST and ALT less than 2.5 x upper limit of normal

          -  creatinine less than 1.5 x upper limit of normal OR creatinine clearance at least 60
             ml/min/1.73 m2

          -  fasting serum cholesterol less than 350

          -  fasting serum triglycerides less than 400

          -  PT or INR less than 1.3 x upper limit of normal

          -  normal urinalysis

          -  Ability to understand and sign the informed consent document

        Exclusion Criteria:

          -  Prior chemotherapy or radiotherapy within 3 weeks of entering the study (6 weeks for
             nitrosoureas or mitomycin C)

          -  Prior treatment with a tyrosine kinase inhibitor within 10 days of entering the study

          -  History of pulmonary hypertension or pneumonitis

          -  Patients may not be receiving other investigational agents

          -  Prior therapy with rapamycin, rapamycin analogues, or tacrolimus

          -  Uncontrolled brain metastases

          -  History of grade 3 or 4 hypersensitivity to macrolide antibiotics

          -  Concurrent treatment with immunosuppressive agents other than a stable (for more than
             2 weeks) dose of corticosteroids

          -  Uncontrolled intercurrent illness

          -  Pregnancy or breast feeding

          -  HIV-positive patients on combination antiretroviral therapy

          -  Grade 3 or 4 proteinuria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Loeb, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Thornton KA, Chen AR, Trucco MM, Shah P, Wilky BA, Gul N, Carrera-Haro MA, Ferreira MF, Shafique U, Powell JD, Meyer CF, Loeb DM. A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer. 2013 Aug 15;133(4):997-1005. doi: 10.1002/ijc.28083. Epub 2013 Mar 4.</citation>
    <PMID>23382028</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2009</study_first_submitted>
  <study_first_submitted_qc>July 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <last_update_submitted>November 25, 2014</last_update_submitted>
  <last_update_submitted_qc>November 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteosarcoma</keyword>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>rhabdomyosarcoma</keyword>
  <keyword>leiomyosarcoma</keyword>
  <keyword>Ewing's sarcoma</keyword>
  <keyword>chondrosarcoma</keyword>
  <keyword>liposarcoma</keyword>
  <keyword>malignant fibrous histiocytoma</keyword>
  <keyword>malignant peripheral nerve sheath tumor</keyword>
  <keyword>pleiomorphic sarcoma</keyword>
  <keyword>spindle cell sarcoma</keyword>
  <keyword>synovial sarcoma</keyword>
  <keyword>cancer stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 7, 2015</submitted>
    <returned>May 27, 2015</returned>
    <submitted>August 11, 2016</submitted>
    <returned>October 4, 2016</returned>
    <submitted>October 21, 2016</submitted>
    <returned>December 13, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

